<DOC>
	<DOC>NCT02745639</DOC>
	<brief_summary>This was a prospective phase II study on patients with locally advanced rectal cancer or local recurrence, to evaluate the pathological response and resectability of a neoadjuvant treatment based on the use of a combined treatment with VMAT-SIB and two drugs chemotherapy ( XELOX).</brief_summary>
	<brief_title>Preoperative Chemoradiation With VMAT-SIB in Rectal Cancer</brief_title>
	<detailed_description>This was a prospective phase II study on patients with LARC or local recurrence, to evaluate the pathological response and resectability of a neoadjuvant treatment based on the use of a combined treatment with VMAT-SIB and two drugs chemotherapy ( XELOX). The primary aim was to asses the pathological response rate. Key secondary aim was the acute toxicity. Secondary aims were local control, disease-free survival (DFS) and overall survival (OS). The follow-up period of each subjects started at the end of combined treatment and concluded after a period of maximum 60 months or until death.</detailed_description>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>i) histologically proven rectal adenocarcinoma (cT34N02 or cT2N12 or locally recurrent) beginning within 12 cm from the anal verge; ii) age â‰¥ 18 years; iii) Eastern Eastern Cooperative Oncology Group (ECOG) performance status of 02. i) history of chemotherapy and/or pelvic radiotherapy; ii) previous treatment with immunotherapy; iii) metastatic patient; iv) presence of active intestinal inflammation or uncontrolled pelvic inflammation; v) pregnant and/or breastfeeding patient.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>rectal cancer</keyword>
	<keyword>radiotherapy</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>VMAT</keyword>
	<keyword>toxicity</keyword>
</DOC>